NCT00327288
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with breast, lung, or prostate cancer that has been previously treated, and the chemotherapy drug docetaxel has been recommended as a treatment option.
- You have already received at least one prior cancer treatment regimen.
- You are able to carry out your normal everyday activities.
- You have not received any cancer treatment for at least 4 weeks before joining the trial.
- If you are female, you must not be pregnant or breastfeeding.
- You are willing to use contraception to avoid pregnancy during the trial.
- You do not have any other serious illnesses.
- You do not have any other active cancer.
- You do not have any serious infections.
- You are not currently taking any other drug treatments for your cancer.
- Your blood counts and blood chemistry test results are within or close to the normal range.
- Having had radiation therapy in the past is allowed.
Who may not be able to join:
- You have cancer that has spread to the brain and is currently active.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the tolerability; determine the maximally tolerated dose (MTD); determine the dose limiting toxicities (DLT) of increasing doses of imexon in combination with standard doses of docetaxel; correlate changes in plasma glutathione (GSH) levels with imexon dose levels
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.